Glecaprevir/pibrentasvir Clinical Trials (2026): 38 Studies for Hepatitis C & Hepatitis C Virus (HCV)
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
38 Glecaprevir/pibrentasvir clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 16 indications (including Hepatitis C & Hepatitis C Virus (HCV)) and 5,178 total planned enrollment. 14 Phase 3 Glecaprevir/pibrentasvir trials and 1 Phase 2, 9 Phase 4 are listed. 3 Glecaprevir/pibrentasvir clinical trials are actively recruiting at 11 U.S. sites across 9 states. Most recent activity: NCT07040319 (Oct 2027).
Where to Participate: All Glecaprevir/pibrentasvir Trial Sites in the U.S. (11 sites across 9 states)
Every actively recruiting Glecaprevir/pibrentasvirtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | USC LA | Los Angeles90089 | NCT07040319 | Map |
| CO | University of Colorado Denver | Aurora80045 | NCT07040319 | Map |
| FL | Univ. of Florida Jacksonville | Jacksonville32209 | NCT07040319 | Map |
| IL | Lurie Children's Hospital of Chicago | Chicago60614 | NCT07040319 | Map |
| MD | Johns Hopkins University Baltimore | Baltimore21287 | NCT07040319 | Map |
| MO | Barnes Jewish Hospital | St Louis63110 | NCT06367465 | Map |
| MO | Washington Univeristy | St Louis63110 | NCT06367465 | Map |
| NY | SUNY Stony Brook | Stony Brook11794 | NCT07040319 | Map |
| NY | Bronx-Lebanon Hospital Center | The Bronx10457 | NCT07040319 | Map |
| TX | Baylor College of Medicine//Texas Children's Hospital | Houston77030 | NCT07040319 | Map |
| VT | White River Junction VAMC | White River Junction05001 | NCT05637879 | Map |
Glecaprevir/pibrentasvir clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | terminated | withdrawn | unknown | approved for marketing | Total |
|---|---|---|---|---|---|---|---|
| Early P1 | 1 | 1 | |||||
| P1/P2 | 1 | 1 | 2 | ||||
| P2 | 1 | 1 | |||||
| P2/P3 | 1 | 3 | 4 | ||||
| P3 | 13 | 1 | 14 | ||||
| P4 | 2 | 2 | 3 | 2 | 9 | ||
| N/A | 1 | 2 | 1 | 2 | 1 | 7 |
Recruiting Glecaprevir/pibrentasvir clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07040319 | Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV | P1/P2 | Hepatitis C | 30 | Jun 2026 |
| NCT06367465 | Feasibility and Acceptability of HCV Treatment in Pregnancy | — | Hepatitis C | 50 | Feb 2024 |
| NCT05637879 | Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder | P2/P3 | PTSD | 92 | Dec 2023 |
Glecaprevir/pibrentasvir clinical trials by indication
Hepatitis C (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07040319 | — | P1/P2 | recruiting | Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV |
| NCT06367465 | — | N/A | recruiting | Feasibility and Acceptability of HCV Treatment in Pregnancy |
| NCT03855917 | STRIVE-4 | P4 | unknown | Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir |
| NCT03981211 | TOPIC | N/A | terminated | Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs |
| NCT05582681 | — | P4 | terminated | HCV Test and Treat Utilizing Simplified HCV Patient Education |
| NCT03776760 | SCALE-C | N/A | unknown | Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination |
| NCT04596475 | HCV | P1/P2 | completed | Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor |
| NCT03492112 | TEMPO | N/A | completed | A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams |
| + 3 more, see All trials below. | ||||
Hepatitis C Virus (HCV) (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04903626 | HCV | P3 | completed | Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) |
| NCT03067129 | DORA | P2/P3 | completed | A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection |
| NCT03089944 | EXPEDITION-8 | P3 | completed | A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis |
| NCT03219216 | GLE | P3 | completed | A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection |
| NCT03235349 | VOYAGE-2 | P3 | completed | Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection |
| NCT03222583 | VOYAGE-1 | P3 | completed | A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection |
| NCT02966795 | ENDURANCE-5 6 | P3 | completed | A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection |
| NCT03212521 | APRI | P3 | completed | Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1 |
| + 1 more, see All trials below. | ||||
PTSD (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05637879 | — | P2/P3 | recruiting | Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder |
| NCT05446857 | — | P2/P3 | completed | Glecaprevir/Pibrentasvir for the Treatment of PTSD |
Kidney Failure (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04515797 | QUICK-CURE | P4 | terminated | QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir |
| NCT03623568 | — | P4 | withdrawn | Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant |
End Stage Renal Disease (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04575896 | — | P4 | completed | Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors |
| NCT04614142 | — | P4 | withdrawn | Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access |
Hepatitis C Virus Infection (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02939989 | MAGELLAN-3 | P3 | completed | Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study |
| NCT03123965 | — | N/A | approved for marketing | Expanded Access to Glecaprevir/ Pibrentasvir |
ESRD (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04682509 | — | Early P1 | completed | A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation |
HCV Infection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04235049 | ECLIPSE | P4 | withdrawn | Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE) |
Hepatitis C Infection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04042740 | PURGE-C | P2 | completed | Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection |
Chronic Hepatitis c (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03941821 | — | N/A | unknown | Glecaprevir/Pibrentasvir Real-world Study in China |
Renal Failure Chronic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03781726 | MYTHIC | P4 | completed | Multi-center Study to Transplant Hepatitis-C Infected Kidneys |
Kidney Transplant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03801707 | — | P2/P3 | completed | Utilization of Hepatitis C Positive Kidneys in Negative Recipients |
Lung Transplant Infection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04017338 | — | P3 | unknown | Transplantation Using Hepatitis C Positive Donors, A Safety Trial |
Hepatitis C, Chronic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03117569 | SMART-C | P3 | completed | Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients |
Hepatitis C, Acute (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02634008 | TARGET3D | P3 | completed | Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P |
Chronic Hepatitis C (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02692703 | MAGELLAN-2 | P3 | completed | A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2) |
Glecaprevir/pibrentasvir pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| STRIVE-4 | NCT03855917 | P4 | unknown | Hepatitis C | 30 | — |
| ECLIPSE | NCT04235049 | P4 | withdrawn | HCV Infection | 0 | — |
| QUICK-CURE | NCT04515797 | P4 | terminated | Kidney Failure | 2 | — |
| MYTHIC | NCT03781726 | P4 | completed | Renal Failure Chronic | 30 | PMID 35155863 |
| ELIMINATEC | NCT03364725 | P4 | unknown | Hepatitis C | 30 | — |
| HCV | NCT04903626 | P3 | completed | Hepatitis C Virus (HCV) | 286 | PMID 41297677 |
| MAGELLAN-3 | NCT02939989 | P3 | completed | Hepatitis C Virus Infection | 33 | PMID 30857780 |
| TARGET3D | NCT02634008 | P3 | completed | Hepatitis C, Acute | 83 | PMID 37771545 |
| EXPEDITION-8 | NCT03089944 | P3 | completed | Hepatitis C Virus (HCV) | 343 | PMID 31682879 |
| GLE | NCT03219216 | P3 | completed | Hepatitis C Virus (HCV) | 100 | PMID 32949786 |
| VOYAGE-2 | NCT03235349 | P3 | completed | Hepatitis C Virus (HCV) | 160 | PMID 32682494 |
| VOYAGE-1 | NCT03222583 | P3 | completed | Hepatitis C Virus (HCV) | 546 | — |
| SMART-C | NCT03117569 | P3 | completed | Hepatitis C, Chronic | 380 | PMID 31655134 |
| ENDURANCE-5 6 | NCT02966795 | P3 | completed | Hepatitis C Virus (HCV) | 84 | PMID 35174470 |
| APRI | NCT03212521 | P3 | completed | Hepatitis C Virus (HCV) | 230 | PMID 31646465 |
| EXPEDITION-5 | NCT03069365 | P3 | completed | Hepatitis C Virus (HCV) | 101 | PMID 31821716 |
| MAGELLAN-2 | NCT02692703 | P3 | completed | Chronic Hepatitis C | 100 | PMID 29672891 |
| PURGE-C | NCT04042740 | P2 | completed | Hepatitis C Infection | 45 | PMID 40736252 |
Terminated and withdrawn Glecaprevir/pibrentasvir trials (6)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT03981211terminatedTreatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs
- NCT05582681terminatedHCV Test and Treat Utilizing Simplified HCV Patient Education
- NCT04235049withdrawnElimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)
- NCT04515797terminatedQUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir
- NCT04614142withdrawnSingle Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access
- NCT03623568withdrawnDirect Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant
All Glecaprevir/pibrentasvir trials (38)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07040319 | Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV | P1/P2 | recruiting | 30 | National Institute of Allergy and Infectious Diseases (NIAID) | Jun 2026 | |
| NCT06367465 | Feasibility and Acceptability of HCV Treatment in Pregnancy | — | recruiting | 50 | Washington University School of Medicine | Feb 2024 | |
| NCT05637879 | Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder | P2/P3 | recruiting | 92 | White River Junction Veterans Affairs Medical Center | Dec 2023 | |
| NCT03855917 | STRIVE-4 | Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir | P4 | unknown | 30 | Kirby Institute | Feb 2020 |
| NCT03981211 | TOPIC | Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs | N/A | terminated | 21 | Kirby Institute | Feb 2021 |
| NCT04017338 | Transplantation Using Hepatitis C Positive Donors, A Safety Trial | P3 | unknown | 40 | Jordan Feld | Aug 2018 | |
| NCT05582681 | HCV Test and Treat Utilizing Simplified HCV Patient Education | P4 | terminated | 8 | Weill Medical College of Cornell University | Nov 2022 | |
| NCT04235049 | ECLIPSE | Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE) | P4 | withdrawn | 0 | University of Maryland, Baltimore | Oct 2021 |
| NCT04903626 | HCV | Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) | P3 | completed | 286 | AbbVie | Aug 2021 |
| NCT05446857 | Glecaprevir/Pibrentasvir for the Treatment of PTSD | P2/P3 | completed | 10 | White River Junction Veterans Affairs Medical Center | Apr 2023 | |
| NCT04682509 | A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation | Early P1 | completed | 20 | NYU Langone Health | Mar 2022 | |
| NCT04575896 | Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors | P4 | completed | 10 | Johns Hopkins University | Nov 2020 | |
| NCT04515797 | QUICK-CURE | QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir | P4 | terminated | 2 | Massachusetts General Hospital | May 2021 |
| NCT04042740 | PURGE-C | Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection | P2 | completed | 45 | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Nov 2019 |
| NCT03067129 | DORA | A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection | P2/P3 | completed | 129 | AbbVie | Mar 2017 |
| NCT03776760 | SCALE-C | Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination | — | unknown | 600 | Kirby Institute | May 2019 |
| NCT03941821 | Glecaprevir/Pibrentasvir Real-world Study in China | — | unknown | 800 | Tongji Hospital | Jun 2019 | |
| NCT04596475 | HCV | Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor | P1/P2 | completed | 12 | University of California, San Diego | May 2021 |
| NCT03781726 | MYTHIC | Multi-center Study to Transplant Hepatitis-C Infected Kidneys | P4 | completed | 30 | Raymond Chung | Apr 2019 |
| NCT03492112 | TEMPO | A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams | N/A | completed | 101 | Kirby Institute | Sep 2019 |
| NCT04614142 | Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access | P4 | withdrawn | 0 | Massachusetts General Hospital | Nov 2020 | |
| NCT02939989 | MAGELLAN-3 | Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study | P3 | completed | 33 | AbbVie | Nov 2016 |
| NCT03801707 | Utilization of Hepatitis C Positive Kidneys in Negative Recipients | P2/P3 | completed | 54 | Ohio State University | Mar 2019 | |
| NCT02634008 | TARGET3D | Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P | P3 | completed | 83 | Kirby Institute | Jun 2016 |
| NCT03623568 | Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant | P4 | withdrawn | 0 | Raymond T. Chung, MD | Feb 2019 | |
| NCT03092375 | Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects | P3 | completed | 177 | University of Florida | Apr 2017 | |
| NCT03089944 | EXPEDITION-8 | A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis | P3 | completed | 343 | AbbVie | Apr 2017 |
| NCT04047680 | eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs | — | completed | 441 | National Taiwan University Hospital | Feb 2015 | |
| NCT03219216 | GLE | A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection | P3 | completed | 100 | AbbVie | Jun 2018 |
| NCT03364725 | ELIMINATEC | Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study | P4 | unknown | 30 | Id Care | Jan 2018 |
| NCT03235349 | VOYAGE-2 | Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection | P3 | completed | 160 | AbbVie | Sep 2017 |
| NCT03222583 | VOYAGE-1 | A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection | P3 | completed | 546 | AbbVie | Oct 2017 |
| NCT03117569 | SMART-C | Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients | P3 | completed | 380 | Kirby Institute | Aug 2017 |
| NCT02966795 | ENDURANCE-5 6 | A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection | P3 | completed | 84 | AbbVie | Jan 2017 |
| NCT03212521 | APRI | Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1 | P3 | completed | 230 | AbbVie | Aug 2017 |
| NCT03069365 | EXPEDITION-5 | A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment | P3 | completed | 101 | AbbVie | Mar 2017 |
| NCT02692703 | MAGELLAN-2 | A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2) | P3 | completed | 100 | AbbVie | Apr 2016 |
| NCT03123965 | Expanded Access to Glecaprevir/ Pibrentasvir | — | approved for marketing | 0 | AbbVie | — |
Glecaprevir/pibrentasvir clinical trials: frequently asked questions
- How many Glecaprevir/pibrentasvir clinical trials are there?
- 38 Glecaprevir/pibrentasvir clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 23 are marked completed.
- Are Glecaprevir/pibrentasvir clinical trials recruiting in 2026?
- Yes — 3 Glecaprevir/pibrentasvir trials are actively recruiting in 2026, with 11 U.S. sites across 9 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Glecaprevir/pibrentasvir being studied for?
- Glecaprevir/pibrentasvir is being studied for Hepatitis C, Hepatitis C Virus (HCV), HCV, End Stage Renal Disease, Chronic Hepatitis c and 31 more. The trials are grouped by indication on this page.
- What phase is Glecaprevir/pibrentasvir in?
- Glecaprevir/pibrentasvir clinical trials span 9 Phase 4, 14 Phase 3, 1 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Glecaprevir/pibrentasvir clinical trials?
- The lead sponsor across the most Glecaprevir/pibrentasvir trials is AbbVie, with 19 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Glecaprevir/pibrentasviras an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: